Sex- and hepatocyte PPARγ-dependent effects of an obesogenic dietary approach to induce MASH with fibrosis in mice

This study demonstrates that a specific high-fat, high-cholesterol, and fructose-supplemented diet successfully induces obesity and MASLD in both male and female mice, but progression to MASH with fibrosis occurs exclusively in males through a hepatocyte PPARγ-dependent mechanism involving the downregulation of methionine metabolism.

The Gist

Imagine your liver is a busy, high-end factory. Its job is to process food, filter toxins, and keep your body running smoothly. But what happens when you flood this factory with too much junk food, sugar, and bad fats? The factory gets overwhelmed, starts leaking oil (fat), catches fire (inflammation), and eventually, the walls start to scar over (fibrosis). This is a condition called MASH (Metabolic dysfunction-Associated Steatohepatitis), a severe form of fatty liver disease.

For years, scientists have struggled to build a perfect "mini-liver" in a mouse to study this disease. Many mouse diets either made the mice too skinny (which doesn't match real human obesity) or didn't cause enough scarring to be useful.

This paper introduces a new, "super-charged" diet for mice that finally solves these problems. Here is the story of what they found, broken down simply:

1. The "Magic" Diet: The Sugar-Soaked Lard Burger

The researchers tried two different "bad" diets on mice that were already a bit overweight from eating regular high-fat food.

• Diet A (The Old Way): A diet with some trans-fats and a lot of sugar mixed right into the food.
  • The Result: It made the mice's livers sick, but it actually made them lose weight and become more sensitive to insulin. This is weird! Real humans with fatty liver disease are usually obese and have diabetes. So, this diet wasn't a good model for real life.
• Diet B (The New Way - HFC+Fr): A diet made of lard (animal fat), cholesterol, and fructose (sugar) given in the drinking water.
  • The Result: This was the winner. It acted like a "super-fuel" for obesity. The mice gained massive amounts of weight and body fat, developed insulin resistance (pre-diabetes), and their livers got clogged with fat. It perfectly mimicked the human condition of an obese person with a fatty liver.

2. The Great Gender Divide: Why Only the Boys Got Sick

Here is where the story gets fascinating. The researchers fed this "Magic Diet" to both male and female mice.

• The Females: They got fat and had fatty livers (steatosis), just like the males. But their livers stayed relatively clean. They didn't develop the dangerous inflammation or the scarring (fibrosis). They were like a factory that was messy but hadn't caught fire yet.
• The Males: They got fat, had fatty livers, and then their livers exploded into MASH. They developed severe inflammation and started building scar tissue (fibrosis), which is the dangerous step toward liver failure.

The Analogy: Think of the liver as a house. Both male and female mice were given a house full of clutter (fat). But only the male houses caught fire and started crumbling (MASH/Fibrosis). The female houses, while messy, somehow resisted the fire.

3. The Culprit: The "Grease Trap" (PPARγ)

Why did the males get sick and the females didn't? The researchers found a specific protein in the liver cells called PPARγ.

• What it does: Think of PPARγ as a grease trap or a storage manager. When activated, it tells the liver cells, "Hey, let's store all this extra fat right here inside the cell!"
• The Problem: In the male mice, the "Magic Diet" turned this manager ON way too hard. The liver cells stuffed themselves with fat, got stressed, and started the chain reaction that led to inflammation and scarring.
• The Fix: The researchers used genetic engineering to turn off this PPARγ manager in the male mice.
  • Result: When they turned off PPARγ, the male mice still got fat (because the diet was so powerful), but their livers did not develop MASH or scarring. The "fire" was put out.

4. The Hidden Saboteur: Methionine (The Body's "Repair Kit")

The study also looked at a chemical process called methionine metabolism. You can think of methionine as the body's repair kit or "construction crew" that fixes damaged cells and keeps things running smoothly.

• In the sick male mice, the overactive PPARγ manager kicked the repair crew out of the building. Without this crew, the liver couldn't fix the damage caused by the fat, leading to more scarring.
• When the researchers turned off PPARγ, the repair crew (methionine metabolism) stayed active, and the liver stayed healthy.
• Interestingly, in the female mice, the repair crew seemed to stay active naturally, which is why they didn't get as sick, even though they were on the same bad diet.

The Big Takeaway

This paper tells us three main things:

1. We finally have a better mouse model: This new diet (Lard + Cholesterol + Fructose water) creates a mouse that is obese, diabetic, and has a fatty liver, just like a real human patient.
2. Men and women are different: Even with the same bad diet, male mice are much more likely to develop the dangerous, scarring version of liver disease than females.
3. The "Grease Trap" is the villain: The protein PPARγ is the main reason the male livers got so damaged. If we can find a way to block PPARγ specifically in the liver, we might be able to stop fatty liver disease from turning into the dangerous, scarred version (MASH) in men.

In short: The researchers found a diet that makes mice look exactly like obese humans with liver disease. They discovered that men are more vulnerable to the scarring stage of this disease because of a specific protein that blocks the liver's natural repair system. Blocking this protein could be the key to saving livers from permanent damage.

Technical Summary

1. Problem Statement

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are major global health challenges. A significant gap exists in preclinical research regarding the generation of mouse models that accurately recapitulate the human phenotype of MASH with fibrosis accompanied by severe obesity and peripheral metabolic dysfunction (insulin resistance).

• Limitations of existing models:
  • Nutrient-deficient diets (e.g., MCD): Induce rapid MASH and fibrosis but reduce adiposity and improve insulin sensitivity, failing to mimic the metabolic syndrome seen in humans.
  • Standard High-Fat (HF) diets: Induce obesity and steatosis but often fail to progress to MASH with fibrosis within a reasonable timeframe (<1 year) without additional stressors.
  • Previous HFCF diets (High-Fat, Cholesterol, Fructose): Used by the authors previously, these induced MASH but paradoxically reduced adiposity and improved insulin resistance in obese mice, limiting their translational relevance.

The study aims to develop and validate a new dietary model that induces obesity, insulin resistance, and MASH with fibrosis simultaneously, while investigating the specific roles of sex and hepatocyte Peroxisome Proliferator-Activated Receptor gamma (PPARγ) in disease progression.

2. Methodology

The study utilized C57BL/6J background mice, specifically *hepatocyte-specific Pparg knockout (PpargΔHep)* mice generated via AAV8-TBG-Cre injection, alongside control (floxed) littermates.

• Dietary Interventions:

  • Baseline: Mice were first fed a High-Fat (HF) diet (60% kcal from lard) for 16 weeks to induce pre-existing obesity and insulin resistance.
  • Comparison Cohorts (Cohorts 1 & 2): Obese mice were switched to either:
    • HFCF Diet: 40% kcal fat (corn oil), 2% cholesterol, 22% fructose (known to reduce adiposity).
    • HFC+Fr Diet (New Model): 60% kcal fat (lard), 2% cholesterol, supplemented with 10% fructose in drinking water.
  • Long-term Cohort (Cohort 3): Both male and female mice (control and PpargΔHep) were fed the HFC+Fr diet for 24 weeks to assess sex differences.
  • Metabolic Cohort (Cohort 4): Male mice fed HFC+Fr were assessed for metabolic rate using Promethion systems.

• Duration: 8 weeks (short-term comparison) and 24 weeks (long-term sex comparison).

• Key Analyses:

  • Phenotyping: Body composition (fat/lean mass), glucose tolerance tests (GTT), plasma lipids, insulin, and ALT.
  • Histology: H&E staining for MASLD Activity Score (NAS); Picrosirius Red for fibrosis quantification.
  • Molecular Biology: qPCR, Western Blot (PPARγ, CIDEC, BHMT, COL1A1), and RNA-seq analysis of liver tissue.
  • Statistical Analysis: Two-way ANOVA, t-tests, and ANCOVA for metabolic data.

3. Key Contributions

1. Development of a Clinically Relevant Model: The authors introduced the HFC+Fr diet (60% lard, 2% cholesterol, 10% fructose in water), which successfully induces severe obesity, insulin resistance, and MASH with fibrosis in mice, overcoming the "adiposity-reducing" side effect of previous HFCF models.
2. Sex-Specific Pathogenesis: The study demonstrates that while the diet induces MASLD (steatosis) in both sexes, the progression to MASH with fibrosis is strictly male-specific under these conditions.
3. Hepatocyte PPARγ as a Driver: The research confirms that hepatocyte PPARγ is a critical driver of MASH progression and fibrosis in males, specifically through the dysregulation of methionine metabolism.
4. Mechanistic Insight: The study links hepatocyte PPARγ activity to the downregulation of methionine cycle genes (Gnmt, Pemt, Bhmt), suggesting a novel mechanism for MASH progression.

4. Key Results

A. Comparison of HFCF vs. HFC+Fr Diets (Short-term, 8 weeks)

• Adiposity: The HFCF diet reduced body weight and fat mass in pre-obese mice. In contrast, the HFC+Fr diet promoted further body weight and fat mass gain, maintaining the obese phenotype.
• Liver Pathology: Both diets increased liver steatosis and inflammation. However, only the HFC+Fr diet induced significant fibrosis and MASH (NAS > 5) in male mice within 8 weeks.
• PPARγ Role: In HFC+Fr-fed males, hepatocyte Pparg knockout (PpargΔHep) significantly reduced liver weight, ALT levels, MASLD activity scores, and fibrosis.

B. Sex Differences in Long-term HFC+Fr Feeding (24 weeks)

• Obesity & Metabolism: Both male and female mice developed severe obesity, hyperinsulinemia, and glucose intolerance.
• Liver Disease:
  • Males: Developed severe steatosis, hepatocyte ballooning, inflammation, and significant fibrosis (MASH).
  • Females: Developed steatosis and inflammation but did not progress to significant fibrosis or MASH (NAS remained lower than males).
• PPARγ Dependency:
  • Hepatocyte PPARγ expression increased in both sexes.
  • However, PpargΔHep only prevented MASH progression, fibrosis, and the upregulation of pro-fibrotic genes (Col1a1, Timp1) in males.
  • In females, PpargΔHep had minimal impact on liver histology or fibrosis markers, suggesting female protection is independent of hepatocyte PPARγ in this context (potentially due to estrogen signaling).

C. Molecular Mechanisms

• PPARγ Target Genes: PPARγ target genes (Cidea, Cidec) were upregulated in HFC+Fr-fed males but not females.
• Methionine Metabolism: The HFC+Fr diet downregulated key methionine metabolism genes (Gnmt, Pemt, Bhmt) in males.
  • Crucial Finding: PpargΔHep reversed this downregulation in males, restoring Gnmt, Pemt, and Bhmt expression.
  • This suggests hepatocyte PPARγ actively suppresses methionine metabolism, leading to homocysteine accumulation and cellular stress, driving fibrosis in males.
• Transcriptomics (RNA-seq):
  • Males showed 2,049 differentially expressed genes (DEGs) vs. 157 in females.
  • Male livers showed upregulation of inflammation/immune response and downregulation of methionine metabolism/mitochondrial function.
  • PpargΔHep in males restored amino acid metabolism pathways and reduced immune response signatures.

5. Significance

• Translational Relevance: The HFC+Fr diet provides a robust, clinically relevant mouse model that mimics the full spectrum of human MASH: obesity, metabolic syndrome, steatosis, inflammation, and fibrosis. This addresses a critical bottleneck in drug development for NASH/MASH.
• Sexual Dimorphism: The study highlights that MASH progression is not uniform across sexes in this model, emphasizing the need for sex-specific therapeutic strategies. The female resistance to fibrosis despite high PPARγ expression suggests protective hormonal mechanisms.
• Therapeutic Target: The identification of hepatocyte PPARγ as a negative regulator of methionine metabolism offers a new mechanistic target. Inhibiting hepatocyte PPARγ activity (or restoring methionine metabolism) could potentially halt the progression from steatosis to fibrosis in male patients.
• Mechanistic Clarity: The paper elucidates that the progression to MASH is not merely a result of lipid accumulation but is driven by specific transcriptional dysregulation (PPARγ-mediated suppression of methionine cycle) that is sex-dependent.

In conclusion, this study validates the HFC+Fr diet as a superior model for studying obesity-driven MASH and establishes hepatocyte PPARγ as a sex-specific driver of fibrosis via the dysregulation of hepatic methionine metabolism.